Modified release formulation

Abstract

Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,45,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

1 - 12 . (canceled) 
     
     
         13 . A stable modified release formulation comprising (-)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester in free base form as active pharmaceutical ingredient and a modified release agent, wherein the modified release agent is hydroxy propyl methylcellulose, such that the active pharmaceutical ingredient is released from the formulation in a controlled fashion over a period of 6-7 hours such that at least 80% of the active pharmaceutical ingredient has been released at the end of this period, and wherein the formulation exhibits a similar or decreased release rate inethanol containing media as compared to an aqueous media with 0.5% LDAO, and
 wherein (-)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester in free base form is present in about 200 mg.   
     
     
         14 . The modified release formulation according to  claim 13  having the following release characteristics in water: about 14% to about 20% after 60 minutes; about 51% to about 61% after 180 minutes; about 67% to about 77% after 240 minutes; about 90% to about 95% after 360 minutes; and about 95% to about 99% after 420 minutes. The before mentioned release characteristics are obtained by using standard dissolution rate equipment (paddle according to e.g. USP) at 100 rpm with 900 ml of Water+0.5% LDAO. 
     
     
         15 . The modified release formulation according to  claim 13  further comprising a coating. 
     
     
         16 . The modified release formulation according to  claim 13  in form of a single unit dosage form comprising 200 mg (-)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester in free base form, about 69 mg to about 135 mg hypromellose (type 2208 characterized by viscosities between about 80 to about 120 cP (20° C.)), about 20 mg to about 160 mg lactose monohydrate, about 3 mg to about 38 mg sodium starch glycolate, about 2 mg to about 4.5 mg Magnesium stearate and about 1 mg to about 2.2 mg colloidal silicon dioxide. 
     
     
         17 . The modified release formulation according to  claim 13  wherein (-)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester in free base form is present in an amount of about 25-250 mg. 
     
     
         18 . The modified release formulation according to  claim 13  in single unit dosage form compressed to round tablets with a diameter of about 8 mm. 
     
     
         19 . The modified release formulation according to  claim 13  in single unit dosage form compressed to round tablets with a diameter of about 11 mm. 
     
     
         20 . A process for the production of a modified release formulation of  claim 13 ,
 comprising
 (i) mixing AFQ056 with filler, binder and disintegrant in a high shear granulator 
 (ii) adding purified water under mixing 
 (iii) kneading the mixture in a high shear granulator 
 (iv) passing the granulate through a screen using a screening mill 
 (v) drying the granulate in a fluid bed dryer 
 (vi) mixing the dry granulate with a modified release agent, filler and glidant followed by consecutive sieving using screening mill and mixing in a diffusion mixer 
 (vii) sieving a lubricant and adding to the mixture from the diffusion mixer 
 (viii) forming the composition 
   
     
     
         21 . A method of treatment of Parkinson's disease L-dopa induced dyskinesia, Fragile X syndrome (Martin-Bell syndrome), dyskinesia in Fragile X syndrome, obsessive compulsory disorders, autism, cystitis, and for the treatment, prevention or delay of progression of acute, traumatic and chronic degenerative processes of the nervous system, such as Parkinson's disease, senile dementia, Alzheimer's disease, huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases such as schizophrenia and anxiety, depression, pain, itch and drug abuse such as alcohol and nicotine abuse and cocaine use disorders comprising administration of the formulation of  claim 13  to a patient in need thereof.